Effective April 1, 2018 J Espino, Director of RODS Laboratory, assumed oversight of the NRDM as Fuchiang (Rich) Tsui accepts position at University of PA/Children's Hospital of Philadelphia. 

Reference Details
Lee, B. Y., Tai, J. H., McGlone, S. M., Bailey, R. R., Wateska, A. R., Zimmer, S. M., Zimmerman, R. K. and Wagner, M. M. (2012), "The potential economic value of a 'universal' (multi-year) influenza vaccine", Influenza Other Respi Viruses, 6, 3: 167--175.

Limitations of the current annual influenza vaccine have led to ongoing efforts to develop a 'universal' influenza vaccine, i.e., one that targets a ubiquitous portion of the influenza virus so that the coverage of a single vaccination can persist for multiple years. To estimate the economic value of a 'universal' influenza vaccine compared to the standard annual influenza vaccine, starting vaccination in the pediatric population (2-18 year olds), over the course of their lifetime. Monte Carlo decision analytic computer simulation model. Universal vaccine dominates (i.e., less costly and more effective) the annual vaccine when the universal vaccine cost ≤ $100/dose and efficacy ≥ 75% for both the 5- and 10-year duration. The universal vaccine is also dominant when efficacy is ≥ 50% and protects for 10 years. A $200 universal vaccine was only cost-effective when ≥ 75% efficacious for a 5-year duration when annual compliance was 25% and for a 10-year duration for all annual compliance rates. A universal vaccine is not cost-effective when it cost $200 and when its efficacy is ≤ 50%. The cost-effectiveness of the universal vaccine increases with the duration of protection. Although development of a universal vaccine requires surmounting scientific hurdles, our results delineate the circumstances under which such a vaccine would be a cost-effective alternative to the annual influenza vaccine.
© 2020 Real-time Outbreak and Disease Surveillance Laboratory
Joomla! is Free Software released under the GNU/GPL License.